{"gene":"TNFRSF25","run_date":"2026-04-28T21:42:59","timeline":{"discoveries":[{"year":2002,"finding":"TL1A (TNFSF15) is the cognate ligand for DR3 (TNFRSF25) and decoy receptor TR6/DcR3. TL1A binding to DR3 induces NF-κB activation and apoptosis in DR3-expressing cell lines, and acts as a T cell costimulator increasing IL-2 responsiveness and secretion of proinflammatory cytokines. TR6-Fc protein antagonizes these signaling events.","method":"Ligand-receptor binding assays, NF-κB reporter assays, apoptosis assays, cytokine secretion assays in vitro and in vivo T cell costimulation experiments","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods (binding, reporter, functional assays) in a highly cited foundational paper; replicated by subsequent studies","pmids":["11911831"],"is_preprint":false},{"year":2003,"finding":"TL1A-DR3 interaction triggers formation of a signaling complex containing TRADD, TRAF2, and RIP, and activates NF-κB and ERK/JNK/p38 MAPK pathways. NF-κB activation prevents DR3-mediated apoptosis via upregulation of c-IAP2; inhibition of c-IAP2 by RNAi sensitizes cells to TL1A-induced apoptosis.","method":"Co-immunoprecipitation of DR3 signaling complex, NF-κB pathway inhibitors, MAPK inhibitors, RNAi knockdown of c-IAP2, apoptosis assays in TF-1 cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — reciprocal Co-IP of signaling complex, RNAi functional validation, and pathway inhibitor studies with clear mechanistic readouts","pmids":["12882979"],"is_preprint":false},{"year":1997,"finding":"TNFRSF25 (LARD) contains a death domain and induces spontaneous apoptosis when overexpressed in 293T cells. Expression is lymphocyte-specific (T and B cells). Alternative pre-mRNA splicing generates at least 11 isoforms; full-length membrane-bound isoform predominates after T cell activation in a programmed splicing switch.","method":"Molecular cloning, overexpression in 293T cells (apoptosis assay), RT-PCR/Northern blot for isoform characterization, expression analysis across cell types","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — original cloning paper with functional overexpression assay and detailed isoform characterization; highly cited foundational study","pmids":["9114039"],"is_preprint":false},{"year":2008,"finding":"DR3 (TNFRSF25) is the receptor responsible for TL1A-induced T cell costimulation. DR3 is required on T cells for immunopathology, local T cell accumulation, and cytokine production in EAE and allergic lung inflammation models. DR3 is not required for in vivo T cell priming or effector subset polarization. Dendritic cells are identified as the likely source of TL1A during T cell activation.","method":"DR3-deficient mouse (genetic knockout), EAE and allergic lung inflammation disease models, T cell transfer experiments, flow cytometry","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — clean knockout mouse with defined cellular phenotypes in multiple disease models; highly cited study","pmids":["18571443"],"is_preprint":false},{"year":2008,"finding":"DR3 (TNFRSF25) expression is selectively elevated in Th17 cells. TL1A promotes proliferation of effector Th17 cells via DR3. TL1A-deficient dendritic cells have reduced capacity to support Th17 differentiation and proliferation. TL1A is required for optimal Th17 differentiation and effector function during EAE.","method":"TL1A-knockout mouse generation, EAE model, flow cytometry for Th17 markers, DC-T cell co-culture assays","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — TL1A KO mouse with multiple orthogonal readouts (in vitro differentiation, in vivo EAE); highly cited","pmids":["18411337"],"is_preprint":false},{"year":2010,"finding":"TNFRSF25 (TNFR25) is constitutively and highly expressed by CD4+FoxP3+ Tregs. Agonistic signaling through TNFR25 (via antibody 4C12) induces rapid and selective expansion of pre-existing Tregs in vivo (up to 30-35% of CD4+ T cells within 4 days). This Treg expansion requires TCR engagement with MHC class II, IL-2 receptor signaling, and Akt signaling, but not CD80/CD86 costimulation, and is rapamycin-insensitive. TNFR25-expanded Tregs suppress allergic lung inflammation in vivo.","method":"Agonistic monoclonal antibody (4C12) treatment in mice, flow cytometry for Treg expansion, signaling inhibitor studies, allergic lung inflammation mouse model","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (in vivo expansion, signaling pathway dissection, disease model) in a single rigorous study","pmids":["20890040"],"is_preprint":false},{"year":2006,"finding":"TL1A and DR3 interaction promotes IFN-γ secretion in activated T cells. TL1A acts preferentially on memory CD4+/CD45RBlo T cells to induce proliferation. TL1A synergizes with IL-12/IL-18 pathway and with low-dose TCR stimulation to induce IFN-γ via an IL-18-independent pathway. DR3 mRNA undergoes alternative splicing upon lymphocyte activation, upregulating the complete/transmembrane form.","method":"RT-PCR for DR3 isoform analysis, T cell proliferation assays, cytokine secretion assays (IFN-γ), pathway inhibitor studies, two murine ileitis models","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal functional assays with defined signaling pathway dissection in two independent animal models","pmids":["16698931"],"is_preprint":false},{"year":2000,"finding":"TWEAK does not interact with WSL-1/TRAMP (DR3) in in vitro binding assays. TWEAK binds to cells not expressing DR3 on their surface and retains biological activity in cells from DR3 knockout mice, demonstrating that DR3 is not the major receptor for TWEAK.","method":"In vitro binding assays with human and murine TWEAK, cell surface expression analysis, DR3 knockout mouse cells","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro binding assay plus KO mouse validation refuting a proposed receptor-ligand pair","pmids":["11094155"],"is_preprint":false},{"year":2011,"finding":"TNFRSF25 triggering by TL1A promotes proliferation and accumulation of antigen-specific CD8+ T cells and their differentiation into CTLs in vivo. TNFRSF25 also functions as a costimulatory receptor for memory CD8+ T cells, enhancing secondary expansion of endogenous antigen-specific memory CD8+ T cells.","method":"Ectopic TL1A expression on plasmacytomas, OT-I TCR transgenic T cell adoptive transfer, in vivo TL1A treatment, flow cytometry for CTL differentiation and proliferation","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — clean in vivo functional assays with transgenic T cells, single lab study","pmids":["21688261"],"is_preprint":false},{"year":2014,"finding":"Atsttrin (a progranulin-derived molecule) directly binds to TNFRSF25 (DR3). The first three cysteine-rich domains (CRD) in the extracellular portion of DR3 are required for Atsttrin binding. Atsttrin inhibits the interaction between DR3 and TL1A, suppresses TL1A-stimulated target gene expression, and neutralizes TL1A-enhanced osteoclastogenesis in vitro.","method":"Direct binding assays (ELISA/pulldown), domain deletion mutants of DR3, competitive binding assay, osteoclastogenesis assay, DSS colitis model","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — direct binding with domain mapping and functional competition assays; single lab","pmids":["24651300"],"is_preprint":false},{"year":2012,"finding":"TNFRSF25 agonist antibody (4C12)-mediated Treg expansion in vivo delays cardiac allograft rejection, associated with increased Foxp3+ Tregs within the graft and decreased infiltration of inflammatory cells.","method":"In vivo TNFRSF25 agonist antibody treatment, fully MHC-mismatched heterotopic heart transplant model, flow cytometry, histopathology, qRT-PCR","journal":"Transplantation","confidence":"Medium","confidence_rationale":"Tier 2 — defined cellular mechanism (Treg expansion) linked to functional outcome in transplant model; single lab","pmids":["22902792"],"is_preprint":false},{"year":2013,"finding":"TNFRSF25 ligation by TL1A leads to recruitment of TRAF2 and TRADD in primary T cells, with downstream activation of NFκB and PI3K/Akt signaling pathways. These pathways are dependent on coordinated engagement of the TCR and IL-2 receptor, leading to constitutive proliferation of CD4+FoxP3+ Tregs.","method":"Co-immunoprecipitation, signaling pathway inhibitors, primary T cell stimulation assays","journal":"Immunologic research","confidence":"Medium","confidence_rationale":"Tier 2-3 — review incorporating co-IP and pathway inhibitor data; mechanistic claim supported by prior experimental work","pmids":["24242819"],"is_preprint":false},{"year":2017,"finding":"The extracellular region of DR3 directly binds to Galectin-9, and Galectin-9 associates with DR3 in Tregs. DR3 agonist-mediated expansion of CD4+Foxp3+ Tregs and suppression of EAE and allergic lung inflammation requires Galectin-9, as protective effects are lost in Galectin-9-/- mice.","method":"Direct binding assay (Galectin-9 binding to extracellular DR3), in vitro stimulation of Galectin-9-/- Tregs, EAE and allergic lung inflammation models in Galectin-9-/- mice, flow cytometry","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — direct binding assay plus KO mouse in two disease models; single lab","pmids":["28877989"],"is_preprint":false},{"year":2019,"finding":"Activation of DR3 signaling by an agonistic anti-DR3 antibody increases GM-CSF production from ILC3s through the p38 MAPK pathway. GM-CSF causes accumulation of eosinophils, neutrophils and myeloid cells, leading to loss of ILC3s from the intestine in an IL-23-dependent manner and exacerbating colitis. Neutralization of TL1A by soluble DR3 ameliorates DSS and anti-CD40 antibody-induced colitis.","method":"Agonistic anti-DR3 antibody treatment, GM-CSF and IL-23 blockade/overexpression experiments, ILC3-depleted mice, DSS and anti-CD40 colitis models, flow cytometry","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal genetic and antibody-based interventions with defined signaling pathway (p38 MAPK → GM-CSF → IL-23 → ILC3 loss)","pmids":["31358760"],"is_preprint":false},{"year":2020,"finding":"Direct TL1A signaling through DR3 on fibroblasts promotes intestinal fibrosis in vivo, independent of immune cell DR3 signaling. TL1A activates the Rho signal transduction pathway in fibroblasts, and inhibition of this pathway modulates TL1A-mediated fibroblast activation and migration.","method":"T cell transfer colitis model in Rag-/-, Rag-/-Dr3-/-, and fibroblast-specific DR3 knockout (Rag-/-Dr3ΔCol1a2) mice, RNA-sequencing of TL1A-stimulated fibroblasts, Rho pathway inhibition, collagen deposition assays","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 — cell-type-specific conditional KO with RNA-seq pathway identification and pharmacological validation; multiple orthogonal approaches","pmids":["33097818"],"is_preprint":false},{"year":2006,"finding":"The DR3 gene promoter CpG island is specifically hypermethylated in rheumatoid arthritis synovial cells, inhibiting DR3 gene expression and DR-3 protein levels, which may provide resistance to apoptosis in RA synovial cells.","method":"Bisulfite genomic sequencing, methylation-specific PCR, luciferase reporter assays with forced methylation by bacterial methylase Sss I, Western blotting","journal":"Arthritis and rheumatism","confidence":"Medium","confidence_rationale":"Tier 2 — promoter reporter assay with forced methylation demonstrates functional consequence; single lab but multiple orthogonal methods","pmids":["16508942"],"is_preprint":false},{"year":2005,"finding":"TL1A and DR3 signaling in macrophage/foam cells induces pro-atherogenic cytokines (TNF-α, MCP-1, IL-8) and matrix metalloproteinase-9 (MMP-9) when combined with IFN-γ stimulation, suggesting a role for the TL1A-DR3 pathway in atherogenesis.","method":"Anti-DR3 monoclonal antibody stimulation and recombinant TL1A treatment of THP-1 macrophage-like cells, cytokine/chemokine ELISA, MMP-9 measurement, immunohistochemistry of carotid plaques","journal":"Cytokine","confidence":"Low","confidence_rationale":"Tier 3 — single cell line stimulation assay without receptor-specific genetic validation; no KO or reconstitution","pmids":["15760679"],"is_preprint":false},{"year":2016,"finding":"DR3 signaling protects against acute DSS colitis; DR3-/- mice show more severe mucosal inflammation and increased mortality. DR3-/- mice are compromised in maintaining CD4+CD25+Foxp3+ regulatory T cells in response to acute mucosal damage, leading to upregulation of Th17 effector responses. TL1A-/- mice similarly show increased susceptibility and reduced Treg numbers.","method":"DR3-/- and TL1A-/- mice, DSS colitis model, Salmonella typhimurium infection model, flow cytometry for Treg and Th17 populations","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — two independent KO mouse strains with mechanistic cellular readouts in multiple disease models","pmids":["27233964"],"is_preprint":false},{"year":2019,"finding":"DR3 activation by TL1A-Ig fusion protein or agonistic antibody (4C12) leads to Treg expansion with upregulation of activation markers ICOS, KLRG-1, PD-1, CD103, and Ki-67. DR3 agonist-mediated Treg expansion in donor mice significantly improves GVHD outcomes in MHC-mismatched hematopoietic cell transplantation recipients.","method":"TL1A-Ig fusion protein and agonistic antibody treatment, bioluminescent imaging, flow cytometry, RNA-sequencing, GVHD mouse model","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple DR3 agonist modalities with RNA-seq characterization and functional disease model; single lab","pmids":["31379829"],"is_preprint":false},{"year":2022,"finding":"TL1A-DR3 axis contributes to airway remodeling in asthma. Non-secreted TL1A (nsTL1A) expressed by airway epithelial cells facilitates TGF-β-induced remodeling. Knockdown of DR3 or TL1A decreases fibrosis-associated protein expression. DR3 knockdown or TL1A knockout partly reverses airway remodeling in OVA-asthma mouse model. Downstream signaling is mediated via the NF-κB pathway.","method":"DR3 siRNA, TL1A siRNA, truncated plasmid overexpression in BEAS-2B cells, DR3 knockdown and TL1A knockout mouse asthma model, RNA-sequencing","journal":"Allergy, asthma & immunology research","confidence":"Medium","confidence_rationale":"Tier 2 — RNAi/KO in vitro and in vivo with RNA-seq pathway analysis; single lab","pmids":["35255540"],"is_preprint":false},{"year":2012,"finding":"Pre-treatment with TNFRSF25 agonistic antibody (MAbT25) before HSV infection effectively reduces severity of subsequent stromal keratitis lesions by expanding Foxp3+ Tregs. Combination of MAbT25 with galectin-9 provides superior lesion control by expanding regulatory T cells expressing CD103 while markedly reducing IFN-γ-producing effector CD4+ T cells.","method":"Agonistic TNFRSF25 antibody treatment in HSV-1 corneal infection model, flow cytometry, galectin-9 combination treatment","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 — functional in vivo study with defined cellular mechanism; single lab","pmids":["22811539"],"is_preprint":false}],"current_model":"TNFRSF25 (DR3) is a death-domain-containing TNF receptor superfamily member expressed primarily on lymphocytes (especially T cells and ILCs) whose sole functional ligand is TL1A (TNFSF15); TL1A binding recruits TRADD, TRAF2, and RIP into a signaling complex that activates NF-κB and PI3K/Akt pathways, promoting T cell costimulation, cytokine production, and apoptosis resistance, while constitutive DR3 signaling on FoxP3+ Tregs drives their selective expansion via TCR- and IL-2R-dependent Akt activation, and context-dependent DR3 activation on ILC3s, fibroblasts, and effector T cell subsets regulates intestinal inflammation, fibrosis, and immune homeostasis through distinct downstream pathways including p38 MAPK and Rho signaling."},"narrative":{"teleology":[{"year":1997,"claim":"Cloning of TNFRSF25 established it as a death-domain-containing receptor with lymphocyte-restricted expression and extensive alternative splicing, raising the question of how isoform switching regulates its function after T cell activation.","evidence":"Molecular cloning, overexpression apoptosis assay in 293T cells, RT-PCR/Northern blot isoform profiling across tissues","pmids":["9114039"],"confidence":"High","gaps":["Functional significance of individual splice isoforms undefined","Endogenous ligand unknown at this point","Mechanism of splicing switch upon T cell activation not characterized"]},{"year":2002,"claim":"Identification of TL1A as the cognate ligand for DR3 resolved the receptor's upstream activation signal and demonstrated that TL1A–DR3 engagement activates NF-κB, induces apoptosis, and costimulates T cells for IL-2 responsiveness and cytokine secretion.","evidence":"Ligand-receptor binding assays, NF-κB reporter assays, apoptosis assays, T cell costimulation with TR6-Fc antagonist","pmids":["11911831"],"confidence":"High","gaps":["Proximal signaling complex composition not yet defined","Balance between apoptosis and survival signaling unexplained","Physiological relevance in vivo not tested"]},{"year":2003,"claim":"Biochemical dissection of the DR3 signaling complex revealed recruitment of TRADD, TRAF2, and RIP, and showed that NF-κB-mediated c-IAP2 upregulation switches DR3 from a death signal to a survival signal, resolving how a death-domain receptor promotes proliferation rather than apoptosis.","evidence":"Co-immunoprecipitation of DR3 complex, NF-κB and MAPK inhibitors, c-IAP2 RNAi in TF-1 cells","pmids":["12882979"],"confidence":"High","gaps":["Role of individual MAPKs (ERK, JNK, p38) in T cell costimulation not distinguished","Signaling in primary T cells vs cell lines not compared","Structural basis of complex assembly unknown"]},{"year":2006,"claim":"Functional studies demonstrated that TL1A–DR3 preferentially costimulates memory CD4+ T cells for IFN-γ production via synergy with IL-12/IL-18 and TCR signals, and confirmed that activation-dependent splicing upregulates the transmembrane DR3 isoform, linking isoform regulation to effector function.","evidence":"T cell proliferation/cytokine assays, RT-PCR isoform analysis, two murine ileitis models","pmids":["16698931"],"confidence":"High","gaps":["Splicing regulatory machinery not identified","Relative contribution of individual cytokine synergy pathways unclear in vivo"]},{"year":2008,"claim":"Genetic knockout studies in mice proved that DR3 on T cells is required for TL1A-mediated immunopathology in EAE and allergic lung disease, and identified Th17 cells as a key effector subset with elevated DR3 expression, while showing DR3 is dispensable for initial T cell priming.","evidence":"DR3-knockout and TL1A-knockout mice in EAE and allergic lung inflammation models, T cell transfer, flow cytometry","pmids":["18571443","18411337"],"confidence":"High","gaps":["Mechanism by which DR3 selectively promotes Th17 expansion not defined at signaling level","Role of DR3 on non-T cell populations not addressed"]},{"year":2010,"claim":"Discovery that DR3 is constitutively expressed on FoxP3+ Tregs and that agonistic DR3 antibody drives rapid, selective Treg expansion in vivo through TCR-, IL-2R-, and Akt-dependent but rapamycin-insensitive signaling fundamentally reframed DR3 as a Treg costimulatory receptor with therapeutic potential.","evidence":"Agonistic mAb 4C12 treatment in mice, signaling pathway inhibitors, allergic lung inflammation model","pmids":["20890040"],"confidence":"High","gaps":["Molecular basis of rapamycin insensitivity not explained","Whether Treg expansion reflects proliferation vs survival not distinguished","Treg suppressive mechanism specifics undefined"]},{"year":2012,"claim":"DR3 agonist-mediated Treg expansion was shown to have therapeutic efficacy in cardiac allograft rejection and HSV stromal keratitis, broadening the translational relevance and demonstrating that combination with Galectin-9 enhances regulatory outcomes.","evidence":"Agonistic anti-DR3 antibody in heart transplant and HSV-1 keratitis mouse models, flow cytometry, histopathology","pmids":["22902792","22811539"],"confidence":"Medium","gaps":["Mechanism of Galectin-9 synergy with DR3 not molecularly defined","Long-term graft tolerance not established","Human Treg responsiveness to DR3 agonism not tested"]},{"year":2016,"claim":"Loss-of-function studies in DR3−/− and TL1A−/− mice demonstrated that constitutive TL1A–DR3 signaling is required to maintain intestinal Tregs during mucosal damage, and its absence tips the balance toward pathogenic Th17 responses, establishing DR3 as a homeostatic regulator of mucosal immunity.","evidence":"DR3-KO and TL1A-KO mice in DSS colitis and Salmonella infection models, flow cytometry for Treg/Th17 balance","pmids":["27233964"],"confidence":"High","gaps":["Cell-intrinsic vs extrinsic requirement for DR3 on Tregs in the gut not separated","Contribution of ILCs not assessed"]},{"year":2017,"claim":"Identification of Galectin-9 as a direct binding partner of DR3's extracellular domain, required for DR3 agonist-mediated Treg expansion and disease protection, revealed a co-receptor requirement for DR3 signaling on Tregs.","evidence":"Direct binding assay, Galectin-9-KO mice in EAE and allergic lung models, in vitro Treg stimulation","pmids":["28877989"],"confidence":"Medium","gaps":["Whether Galectin-9 modifies DR3 signaling complex composition unknown","Structural basis of DR3–Galectin-9 interaction not resolved","Relevance to non-Treg DR3 signaling not tested"]},{"year":2019,"claim":"DR3 signaling on ILC3s was shown to activate p38 MAPK leading to GM-CSF production that drives IL-23-dependent ILC3 depletion and colitis exacerbation, revealing a cell-type-specific pro-inflammatory DR3 signaling axis distinct from its Treg-expanding role.","evidence":"Agonistic anti-DR3 antibody, GM-CSF/IL-23 blockade, ILC3-depleted mice, DSS and anti-CD40 colitis models","pmids":["31358760"],"confidence":"High","gaps":["Molecular basis for differential pathway selection (p38 in ILC3 vs Akt in Tregs) not defined","Role of TRADD/TRAF2 complex in ILC3 not assessed"]},{"year":2020,"claim":"Cell-type-specific knockout demonstrated that TL1A–DR3 signaling directly on fibroblasts, independent of immune cells, promotes intestinal fibrosis through Rho pathway activation, extending DR3 function beyond the immune system to tissue remodeling.","evidence":"Fibroblast-specific DR3 conditional KO (Rag−/−Dr3ΔCol1a2), RNA-seq of TL1A-stimulated fibroblasts, Rho inhibition","pmids":["33097818"],"confidence":"High","gaps":["Specific Rho GTPase family member(s) involved not identified","Whether fibroblast DR3 uses TRADD/TRAF2 complex not tested","Relevance to human fibrotic disease not established"]},{"year":null,"claim":"Key unresolved questions include the structural basis of DR3 signaling complex assembly, the molecular determinants that select between pro-survival (NF-κB/Akt) and pro-inflammatory (p38/Rho) outputs in different cell types, and whether DR3 agonism can be therapeutically harnessed for selective Treg expansion in humans.","evidence":"","pmids":[],"confidence":"Low","gaps":["No crystal structure of DR3 ectodomain or DR3–TL1A complex","Mechanism of cell-type-specific pathway selection (Akt vs p38 vs Rho) unknown","Human clinical validation of DR3 agonist-driven Treg expansion absent"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,1,3,5,13,14]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[2,0,5]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[3,4,5,6,8,17]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[1,2]}],"complexes":[],"partners":["TNFSF15","TRADD","TRAF2","RIPK1","LGALS9"],"other_free_text":[]},"mechanistic_narrative":"TNFRSF25 (DR3) is a death-domain-containing TNF receptor superfamily member expressed predominantly on lymphocytes that functions as a context-dependent costimulatory and pro-survival receptor linking innate and adaptive immune responses. Its sole confirmed ligand, TL1A (TNFSF15), triggers recruitment of TRADD, TRAF2, and RIP into a signaling complex that activates NF-κB, PI3K/Akt, and MAPK pathways; NF-κB-dependent upregulation of c-IAP2 prevents DR3-mediated apoptosis, converting the death-domain signal into a pro-survival and proliferative output [PMID:12882979, PMID:11911831]. DR3 is constitutively expressed at high levels on CD4+FoxP3+ regulatory T cells, where agonistic signaling drives rapid, selective Treg expansion through TCR- and IL-2R-dependent Akt activation in a Galectin-9-dependent manner, conferring protection in models of allergy, transplant rejection, GVHD, and colitis [PMID:20890040, PMID:27233964, PMID:28877989]. Beyond T cells, TL1A–DR3 signaling on ILC3s activates p38 MAPK to induce GM-CSF and modulate intestinal inflammation, and on fibroblasts activates Rho signaling to promote intestinal fibrosis, establishing DR3 as a pleiotropic regulator of mucosal immunity and tissue remodeling [PMID:31358760, PMID:33097818]."},"prefetch_data":{"uniprot":{"accession":"Q93038","full_name":"Tumor necrosis factor receptor superfamily member 25","aliases":["Apo-3","Apoptosis-inducing receptor AIR","Apoptosis-mediating receptor DR3","Apoptosis-mediating receptor TRAMP","Death receptor 3","Lymphocyte-associated receptor of death","LARD","Protein WSL","Protein WSL-1"],"length_aa":417,"mass_kda":45.4,"function":"Receptor for TNFSF12/APO3L/TWEAK. Interacts directly with the adapter TRADD. Mediates activation of NF-kappa-B and induces apoptosis. May play a role in regulating lymphocyte homeostasis","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/Q93038/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TNFRSF25","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TNFRSF25","total_profiled":1310},"omim":[{"mim_id":"604052","title":"TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY, MEMBER 15; TNFSF15","url":"https://www.omim.org/entry/604052"},{"mim_id":"603611","title":"TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 10A; TNFRSF10A","url":"https://www.omim.org/entry/603611"},{"mim_id":"603500","title":"TUMOR NECROSIS FACTOR RECEPTOR 1-ASSOCIATED DEATH DOMAIN PROTEIN; TRADD","url":"https://www.omim.org/entry/603500"},{"mim_id":"603366","title":"TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 25; TNFRSF25","url":"https://www.omim.org/entry/603366"},{"mim_id":"602695","title":"TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY, MEMBER 12; TNFSF12","url":"https://www.omim.org/entry/602695"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Plasma membrane","reliability":"Approved"},{"location":"Actin filaments","reliability":"Approved"},{"location":"Focal adhesion sites","reliability":"Approved"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":42.2},{"tissue":"lymphoid tissue","ntpm":39.8},{"tissue":"pituitary gland","ntpm":26.7}],"url":"https://www.proteinatlas.org/search/TNFRSF25"},"hgnc":{"alias_symbol":["DR3","TRAMP","WSL-1","LARD","WSL-LR","DDR3","TR3","APO-3"],"prev_symbol":["TNFRSF12"]},"alphafold":{"accession":"Q93038","domains":[{"cath_id":"2.10.50.10","chopping":"41-92","consensus_level":"high","plddt":88.7162,"start":41,"end":92},{"cath_id":"1.10.533.10","chopping":"334-416","consensus_level":"high","plddt":89.6116,"start":334,"end":416}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q93038","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q93038-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q93038-F1-predicted_aligned_error_v6.png","plddt_mean":72.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TNFRSF25","jax_strain_url":"https://www.jax.org/strain/search?query=TNFRSF25"},"sequence":{"accession":"Q93038","fasta_url":"https://rest.uniprot.org/uniprotkb/Q93038.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q93038/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q93038"}},"corpus_meta":[{"pmid":"11911831","id":"PMC_11911831","title":"TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator.","date":"2002","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/11911831","citation_count":523,"is_preprint":false},{"pmid":"16452231","id":"PMC_16452231","title":"Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16452231","citation_count":251,"is_preprint":false},{"pmid":"12496841","id":"PMC_12496841","title":"Pathologic progression of autochthonous prostate cancer in the TRAMP model.","date":"1999","source":"Prostate cancer and prostatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/12496841","citation_count":199,"is_preprint":false},{"pmid":"20062804","id":"PMC_20062804","title":"Nrf2 expression is regulated by epigenetic mechanisms in prostate cancer of TRAMP mice.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20062804","citation_count":190,"is_preprint":false},{"pmid":"18411337","id":"PMC_18411337","title":"TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease.","date":"2008","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18411337","citation_count":187,"is_preprint":false},{"pmid":"18571443","id":"PMC_18571443","title":"The TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases.","date":"2008","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/18571443","citation_count":179,"is_preprint":false},{"pmid":"9114039","id":"PMC_9114039","title":"LARD: a new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing.","date":"1997","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9114039","citation_count":175,"is_preprint":false},{"pmid":"22179700","id":"PMC_22179700","title":"Structure of the full human RXR/VDR nuclear receptor heterodimer complex with its DR3 target DNA.","date":"2011","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/22179700","citation_count":158,"is_preprint":false},{"pmid":"23416117","id":"PMC_23416117","title":"Sulforaphane enhances Nrf2 expression in prostate cancer TRAMP C1 cells through epigenetic regulation.","date":"2013","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23416117","citation_count":157,"is_preprint":false},{"pmid":"18776903","id":"PMC_18776903","title":"TRAMP-mediated RNA surveillance prevents spurious entry of RNAs into the Schizosaccharomyces pombe siRNA pathway.","date":"2008","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18776903","citation_count":155,"is_preprint":false},{"pmid":"24067903","id":"PMC_24067903","title":"Apigenin inhibits prostate cancer progression in TRAMP mice via targeting PI3K/Akt/FoxO pathway.","date":"2013","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/24067903","citation_count":149,"is_preprint":false},{"pmid":"16698931","id":"PMC_16698931","title":"Role of TL1A and its receptor DR3 in two models of chronic murine ileitis.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16698931","citation_count":137,"is_preprint":false},{"pmid":"2784477","id":"PMC_2784477","title":"T cells sensitized to synthetic HLA-DR3 peptide give evidence of continuous presentation of denatured HLA-DR3 molecules by HLA-DP.","date":"1989","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/2784477","citation_count":132,"is_preprint":false},{"pmid":"20890040","id":"PMC_20890040","title":"Therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammation.","date":"2010","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/20890040","citation_count":132,"is_preprint":false},{"pmid":"24663492","id":"PMC_24663492","title":"High-lard and high-fish-oil diets differ in their effects on function and dynamic behaviour of rat hepatic mitochondria.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24663492","citation_count":113,"is_preprint":false},{"pmid":"12882979","id":"PMC_12882979","title":"TL1A-induced NF-kappaB activation and c-IAP2 production prevent DR3-mediated apoptosis in TF-1 cells.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12882979","citation_count":105,"is_preprint":false},{"pmid":"22704445","id":"PMC_22704445","title":"Systemic buffers inhibit carcinogenesis in TRAMP mice.","date":"2012","source":"The Journal of urology","url":"https://pubmed.ncbi.nlm.nih.gov/22704445","citation_count":101,"is_preprint":false},{"pmid":"12470639","id":"PMC_12470639","title":"Liganded VDR induces CYP3A4 in small intestinal and colon cancer cells via DR3 and ER6 vitamin D responsive elements.","date":"2002","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12470639","citation_count":97,"is_preprint":false},{"pmid":"16508942","id":"PMC_16508942","title":"Hypermethylated promoter region of DR3, the death receptor 3 gene, in rheumatoid arthritis synovial cells.","date":"2006","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/16508942","citation_count":96,"is_preprint":false},{"pmid":"30972074","id":"PMC_30972074","title":"TL1A (TNFSF15) and DR3 (TNFRSF25): A Co-stimulatory System of Cytokines With Diverse Functions in Gut Mucosal Immunity.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30972074","citation_count":92,"is_preprint":false},{"pmid":"21663793","id":"PMC_21663793","title":"The RNA helicase Mtr4p modulates polyadenylation in the TRAMP complex.","date":"2011","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/21663793","citation_count":86,"is_preprint":false},{"pmid":"19955569","id":"PMC_19955569","title":"TRAMP complex enhances RNA degradation by the nuclear exosome component Rrp6.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19955569","citation_count":85,"is_preprint":false},{"pmid":"19494267","id":"PMC_19494267","title":"Resistance to celiac disease in humanized HLA-DR3-DQ2-transgenic mice expressing specific anti-gliadin CD4+ T cells.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19494267","citation_count":83,"is_preprint":false},{"pmid":"23417976","id":"PMC_23417976","title":"Nuclear RNA surveillance: role of TRAMP in controlling exosome specificity.","date":"2013","source":"Wiley interdisciplinary reviews. RNA","url":"https://pubmed.ncbi.nlm.nih.gov/23417976","citation_count":79,"is_preprint":false},{"pmid":"17052998","id":"PMC_17052998","title":"The aryl hydrocarbon receptor inhibits prostate carcinogenesis in TRAMP mice.","date":"2006","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/17052998","citation_count":78,"is_preprint":false},{"pmid":"15760679","id":"PMC_15760679","title":"Involvement of TL1A and DR3 in induction of pro-inflammatory cytokines and matrix metalloproteinase-9 in atherogenesis.","date":"2005","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/15760679","citation_count":71,"is_preprint":false},{"pmid":"27792915","id":"PMC_27792915","title":"Identification of pork flavour precursors from enzyme-treated lard using Maillard model system assessed by GC-MS and partial least squares regression.","date":"2016","source":"Meat science","url":"https://pubmed.ncbi.nlm.nih.gov/27792915","citation_count":69,"is_preprint":false},{"pmid":"15149738","id":"PMC_15149738","title":"Genistein alters growth factor signaling in transgenic prostate model (TRAMP).","date":"2004","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/15149738","citation_count":67,"is_preprint":false},{"pmid":"6603391","id":"PMC_6603391","title":"HLA-DR3 and DR7 in coeliac disease: immunogenetic and clinical aspects.","date":"1983","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/6603391","citation_count":64,"is_preprint":false},{"pmid":"25175027","id":"PMC_25175027","title":"The molecular architecture of the TRAMP complex reveals the organization and interplay of its two catalytic activities.","date":"2014","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/25175027","citation_count":62,"is_preprint":false},{"pmid":"22532666","id":"PMC_22532666","title":"RNA unwinding by the Trf4/Air2/Mtr4 polyadenylation (TRAMP) complex.","date":"2012","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/22532666","citation_count":61,"is_preprint":false},{"pmid":"24453414","id":"PMC_24453414","title":"The role of TL1A and DR3 in autoimmune and inflammatory diseases.","date":"2013","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/24453414","citation_count":59,"is_preprint":false},{"pmid":"24651300","id":"PMC_24651300","title":"Progranulin-derived Atsttrin directly binds to TNFRSF25 (DR3) and inhibits TNF-like ligand 1A (TL1A) activity.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24651300","citation_count":58,"is_preprint":false},{"pmid":"2413154","id":"PMC_2413154","title":"HLA class II regulation and structure. Analysis with HLA-DR3 and HLA-DP point mutants.","date":"1985","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/2413154","citation_count":58,"is_preprint":false},{"pmid":"21688261","id":"PMC_21688261","title":"Triggering of TNFRSF25 promotes CD8⁺ T-cell responses and anti-tumor immunity.","date":"2011","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21688261","citation_count":56,"is_preprint":false},{"pmid":"20696927","id":"PMC_20696927","title":"Structure and function of the polymerase core of TRAMP, a RNA surveillance complex.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20696927","citation_count":54,"is_preprint":false},{"pmid":"31358760","id":"PMC_31358760","title":"Activation of DR3 signaling causes loss of ILC3s and exacerbates intestinal inflammation.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31358760","citation_count":53,"is_preprint":false},{"pmid":"20593019","id":"PMC_20593019","title":"Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with α-galactosylceramide.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20593019","citation_count":52,"is_preprint":false},{"pmid":"18832702","id":"PMC_18832702","title":"Complexes of two cohorts of CLIP peptides and HLA-DQ2 of the autoimmune DR3-DQ2 haplotype are poor substrates for HLA-DM.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18832702","citation_count":52,"is_preprint":false},{"pmid":"19707589","id":"PMC_19707589","title":"The CCR4-NOT complex physically and functionally interacts with TRAMP and the nuclear exosome.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19707589","citation_count":52,"is_preprint":false},{"pmid":"19597474","id":"PMC_19597474","title":"The role of SPARC in the TRAMP model of prostate carcinogenesis and progression.","date":"2009","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/19597474","citation_count":52,"is_preprint":false},{"pmid":"31882115","id":"PMC_31882115","title":"Influence of lard-based diacylglycerol on rheological and physicochemical properties of thermally induced gels of porcine myofibrillar protein at different NaCl concentrations.","date":"2019","source":"Food research international (Ottawa, Ont.)","url":"https://pubmed.ncbi.nlm.nih.gov/31882115","citation_count":51,"is_preprint":false},{"pmid":"8103522","id":"PMC_8103522","title":"Tyrosine-rich acidic matrix protein (TRAMP) accelerates collagen fibril formation in vitro.","date":"1993","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8103522","citation_count":50,"is_preprint":false},{"pmid":"28877989","id":"PMC_28877989","title":"Regulatory T Cell-Mediated Suppression of Inflammation Induced by DR3 Signaling Is Dependent on Galectin-9.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/28877989","citation_count":50,"is_preprint":false},{"pmid":"12542740","id":"PMC_12542740","title":"Common HLA-B8-DR3 haplotype in Northern India is different from that found in Europe.","date":"2002","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/12542740","citation_count":49,"is_preprint":false},{"pmid":"21911444","id":"PMC_21911444","title":"Bitter melon extract impairs prostate cancer cell-cycle progression and delays prostatic intraepithelial neoplasia in TRAMP model.","date":"2011","source":"Cancer prevention research (Philadelphia, Pa.)","url":"https://pubmed.ncbi.nlm.nih.gov/21911444","citation_count":48,"is_preprint":false},{"pmid":"14518031","id":"PMC_14518031","title":"Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model.","date":"2003","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/14518031","citation_count":48,"is_preprint":false},{"pmid":"26497688","id":"PMC_26497688","title":"Flavokawain A induces deNEDDylation and Skp2 degradation leading to inhibition of tumorigenesis and cancer progression in the TRAMP transgenic mouse model.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26497688","citation_count":47,"is_preprint":false},{"pmid":"16216463","id":"PMC_16216463","title":"Genotoxicity and oxidative stress of the mutagenic compounds formed in fumes of heated soybean oil, sunflower oil and lard.","date":"2005","source":"Toxicology in vitro : an international journal published in association with BIBRA","url":"https://pubmed.ncbi.nlm.nih.gov/16216463","citation_count":47,"is_preprint":false},{"pmid":"11094155","id":"PMC_11094155","title":"Studies on the interaction between TWEAK and the death receptor WSL-1/TRAMP (DR3).","date":"2000","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/11094155","citation_count":46,"is_preprint":false},{"pmid":"24097436","id":"PMC_24097436","title":"Cotranscriptional recruitment of yeast TRAMP complex to intronic sequences promotes optimal pre-mRNA splicing.","date":"2013","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/24097436","citation_count":46,"is_preprint":false},{"pmid":"26775153","id":"PMC_26775153","title":"Properties and oxidative stability of emulsions prepared with myofibrillar protein and lard diacylglycerols.","date":"2016","source":"Meat science","url":"https://pubmed.ncbi.nlm.nih.gov/26775153","citation_count":45,"is_preprint":false},{"pmid":"28400577","id":"PMC_28400577","title":"Fish oil, lard and soybean oil differentially shape gut microbiota of middle-aged rats.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28400577","citation_count":45,"is_preprint":false},{"pmid":"36335520","id":"PMC_36335520","title":"NRF2 modulation in TRAMP mice: an in vivo model of prostate cancer.","date":"2022","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/36335520","citation_count":42,"is_preprint":false},{"pmid":"21837756","id":"PMC_21837756","title":"In vivo pharmacodynamics of indole-3-carbinol in the inhibition of prostate cancer in transgenic adenocarcinoma of mouse prostate (TRAMP) mice: involvement of Nrf2 and cell cycle/apoptosis signaling pathways.","date":"2011","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/21837756","citation_count":40,"is_preprint":false},{"pmid":"25887448","id":"PMC_25887448","title":"The TL1A/DR3/DcR3 pathway in autoimmune rheumatic diseases.","date":"2015","source":"Seminars in arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/25887448","citation_count":39,"is_preprint":false},{"pmid":"26991801","id":"PMC_26991801","title":"Epigenetics Reactivation of Nrf2 in Prostate TRAMP C1 Cells by Curcumin Analogue FN1.","date":"2016","source":"Chemical research in toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/26991801","citation_count":38,"is_preprint":false},{"pmid":"3009607","id":"PMC_3009607","title":"Altered phagocytosis by monocytes from HLA-DR2 and DR3-positive healthy adults is Fc gamma receptor specific.","date":"1986","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/3009607","citation_count":38,"is_preprint":false},{"pmid":"20136438","id":"PMC_20136438","title":"Dietary zinc and prostate cancer in the TRAMP mouse model.","date":"2010","source":"Journal of medicinal food","url":"https://pubmed.ncbi.nlm.nih.gov/20136438","citation_count":37,"is_preprint":false},{"pmid":"22902792","id":"PMC_22902792","title":"Tregs expanded in vivo by TNFRSF25 agonists promote cardiac allograft survival.","date":"2012","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/22902792","citation_count":37,"is_preprint":false},{"pmid":"29247555","id":"PMC_29247555","title":"The triterpenoid corosolic acid blocks transformation and epigenetically reactivates Nrf2 in TRAMP-C1 prostate cells.","date":"2018","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/29247555","citation_count":37,"is_preprint":false},{"pmid":"22496363","id":"PMC_22496363","title":"Changes in glucose tolerance and leptin responsiveness of rats offered a choice of lard, sucrose, and chow.","date":"2012","source":"American journal of physiology. Regulatory, integrative and comparative physiology","url":"https://pubmed.ncbi.nlm.nih.gov/22496363","citation_count":37,"is_preprint":false},{"pmid":"27233964","id":"PMC_27233964","title":"A Novel Role for TL1A/DR3 in Protection against Intestinal Injury and Infection.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/27233964","citation_count":36,"is_preprint":false},{"pmid":"24242819","id":"PMC_24242819","title":"Immunobiology of TNFSF15 and TNFRSF25.","date":"2013","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/24242819","citation_count":35,"is_preprint":false},{"pmid":"39266053","id":"PMC_39266053","title":"Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD.","date":"2025","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/39266053","citation_count":33,"is_preprint":false},{"pmid":"10201931","id":"PMC_10201931","title":"Scanning a DRB3*0101 (DR52a)-restricted epitope cross-presented by DR3: overlapping natural and artificial determinants in the human acetylcholine receptor.","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10201931","citation_count":33,"is_preprint":false},{"pmid":"32748838","id":"PMC_32748838","title":"Quercetin-Resveratrol Combination for Prostate Cancer Management in TRAMP Mice.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32748838","citation_count":33,"is_preprint":false},{"pmid":"10674967","id":"PMC_10674967","title":"HLA associations in type 1 diabetes among patients not carrying high-risk DR3-DQ2 or DR4-DQ8 haplotypes.","date":"1999","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/10674967","citation_count":33,"is_preprint":false},{"pmid":"1541486","id":"PMC_1541486","title":"The evolutionary origin of the HLA-DR3 haplotype.","date":"1992","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/1541486","citation_count":32,"is_preprint":false},{"pmid":"33097818","id":"PMC_33097818","title":"Direct signaling of TL1A-DR3 on fibroblasts induces intestinal fibrosis in vivo.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33097818","citation_count":31,"is_preprint":false},{"pmid":"22956587","id":"PMC_22956587","title":"T cell costimulation by TNFR superfamily (TNFRSF)4 and TNFRSF25 in the context of vaccination.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/22956587","citation_count":30,"is_preprint":false},{"pmid":"25053105","id":"PMC_25053105","title":"High animal fat intake enhances prostate cancer progression and reduces glutathione peroxidase 3 expression in early stages of TRAMP mice.","date":"2014","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/25053105","citation_count":30,"is_preprint":false},{"pmid":"32561742","id":"PMC_32561742","title":"Substrate specificity of the TRAMP nuclear surveillance complexes.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32561742","citation_count":29,"is_preprint":false},{"pmid":"7806299","id":"PMC_7806299","title":"Primate DRB genes from the DR3 and DR8 haplotypes contain ERV9 LTR elements at identical positions.","date":"1995","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/7806299","citation_count":29,"is_preprint":false},{"pmid":"19342694","id":"PMC_19342694","title":"HLA-DQ8 (DQB1*0302)-restricted Th17 cells exacerbate experimental autoimmune encephalomyelitis in HLA-DR3-transgenic mice.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19342694","citation_count":29,"is_preprint":false},{"pmid":"27207661","id":"PMC_27207661","title":"Icaritin suppresses development of neuroendocrine differentiation of prostate cancer through inhibition of IL-6/STAT3 and Aurora kinase A pathways in TRAMP mice.","date":"2016","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/27207661","citation_count":29,"is_preprint":false},{"pmid":"21961053","id":"PMC_21961053","title":"Prevention of Prostate Cancer with Oleanane Synthetic Triterpenoid CDDO-Me in the TRAMP Mouse Model of Prostate Cancer.","date":"2011","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/21961053","citation_count":27,"is_preprint":false},{"pmid":"23103299","id":"PMC_23103299","title":"A multistage-polyepitope vaccine protects against Mycobacterium tuberculosis infection in HLA-DR3 transgenic mice.","date":"2012","source":"Vaccine","url":"https://pubmed.ncbi.nlm.nih.gov/23103299","citation_count":26,"is_preprint":false},{"pmid":"27325372","id":"PMC_27325372","title":"Glutathione Peroxidase 3 Inhibits Prostate Tumorigenesis in TRAMP Mice.","date":"2016","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/27325372","citation_count":26,"is_preprint":false},{"pmid":"35665810","id":"PMC_35665810","title":"Intralymphatic GAD-Alum (Diamyd®) Improves Glycemic Control in Type 1 Diabetes With HLA DR3-DQ2.","date":"2022","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/35665810","citation_count":26,"is_preprint":false},{"pmid":"20661828","id":"PMC_20661828","title":"Mixed tocotrienols inhibit prostate carcinogenesis in TRAMP mice.","date":"2010","source":"Nutrition and cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20661828","citation_count":25,"is_preprint":false},{"pmid":"15926921","id":"PMC_15926921","title":"Hepatic vagotomy alters limbic and hypothalamic neuropeptide responses to insulin-dependent diabetes and voluntary lard ingestion.","date":"2005","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/15926921","citation_count":24,"is_preprint":false},{"pmid":"24045788","id":"PMC_24045788","title":"Immunization with cross-conserved H1N1 influenza CD4+ T-cell epitopes lowers viral burden in HLA DR3 transgenic mice.","date":"2013","source":"Human vaccines & immunotherapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/24045788","citation_count":23,"is_preprint":false},{"pmid":"22811539","id":"PMC_22811539","title":"TNFRSF25 agonistic antibody and galectin-9 combination therapy controls herpes simplex virus-induced immunoinflammatory lesions.","date":"2012","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/22811539","citation_count":23,"is_preprint":false},{"pmid":"22923767","id":"PMC_22923767","title":"Air proteins control differential TRAMP substrate specificity for nuclear RNA surveillance.","date":"2012","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/22923767","citation_count":23,"is_preprint":false},{"pmid":"21625214","id":"PMC_21625214","title":"The Ron receptor promotes prostate tumor growth in the TRAMP mouse model.","date":"2011","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/21625214","citation_count":22,"is_preprint":false},{"pmid":"12474544","id":"PMC_12474544","title":"Derivation of MPR and TRAMP models of prostate cancer and prostate cancer metastasis for evaluation of therapeutic strategies.","date":"2002","source":"Urologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/12474544","citation_count":21,"is_preprint":false},{"pmid":"18490779","id":"PMC_18490779","title":"HLA-DQ6 (DQB1*0601)-restricted T cells protect against experimental autoimmune encephalomyelitis in HLA-DR3.DQ6 double-transgenic mice by generating anti-inflammatory IFN-gamma.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18490779","citation_count":21,"is_preprint":false},{"pmid":"22348196","id":"PMC_22348196","title":"CD161 DEFINES EFFECTOR T CELLS THAT EXPRESS LIGHT AND RESPOND TO TL1A-DR3 SIGNALING.","date":"2011","source":"European journal of microbiology & immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22348196","citation_count":20,"is_preprint":false},{"pmid":"31450308","id":"PMC_31450308","title":"Ultrasound-mediated interfacial protein adsorption and fat crystallization in cholesterol-reduced lard emulsion.","date":"2019","source":"Ultrasonics sonochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31450308","citation_count":20,"is_preprint":false},{"pmid":"28095711","id":"PMC_28095711","title":"Systemic alkalinisation delays prostate cancer cell progression in TRAMP mice.","date":"2017","source":"Journal of enzyme inhibition and medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28095711","citation_count":19,"is_preprint":false},{"pmid":"31980336","id":"PMC_31980336","title":"Cepharanthine blocks TSH receptor peptide presentation by HLA-DR3: Therapeutic implications to Graves' disease.","date":"2020","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/31980336","citation_count":19,"is_preprint":false},{"pmid":"35255540","id":"PMC_35255540","title":"The TL1A-DR3 Axis in Asthma: Membrane-Bound and Secreted TL1A Co-Determined the Development of Airway Remodeling.","date":"2022","source":"Allergy, asthma & immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/35255540","citation_count":19,"is_preprint":false},{"pmid":"31379829","id":"PMC_31379829","title":"Activation of the DR3-TL1A Axis in Donor Mice Leads to Regulatory T Cell Expansion and Activation With Reduction in Graft-Versus-Host Disease.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31379829","citation_count":19,"is_preprint":false},{"pmid":"2835344","id":"PMC_2835344","title":"Two variants of DRw52, DR3, and DQw2 specificities distinguish two different DR3-bearing extended haplotypes.","date":"1988","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/2835344","citation_count":19,"is_preprint":false},{"pmid":"17613006","id":"PMC_17613006","title":"Safingol toxicology after oral administration to TRAMP mice: demonstration of safingol uptake and metabolism by N-acylation and N-methylation.","date":"2007","source":"Drug and chemical toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/17613006","citation_count":19,"is_preprint":false},{"pmid":"30962219","id":"PMC_30962219","title":"Genetic Variation Within the HLA-DRA1 Gene Modulates Susceptibility to Type 1 Diabetes in HLA-DR3 Homozygotes.","date":"2019","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/30962219","citation_count":18,"is_preprint":false},{"pmid":"30511687","id":"PMC_30511687","title":"Association of HLA-DR3 and HLA-DR15 Polymorphisms with Risk of Systemic Lupus Erythematosus.","date":"2018","source":"Chinese medical journal","url":"https://pubmed.ncbi.nlm.nih.gov/30511687","citation_count":17,"is_preprint":false},{"pmid":"33176505","id":"PMC_33176505","title":"Comparative study of dietary fat: lard and sugar as a better obesity and metabolic syndrome mice model.","date":"2020","source":"Archives of physiology and biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33176505","citation_count":17,"is_preprint":false},{"pmid":"26810853","id":"PMC_26810853","title":"Biologics beyond TNF-α inhibitors and the effect of targeting the homologues TL1A-DR3 pathway in chronic inflammatory disorders.","date":"2016","source":"Immunopharmacology and immunotoxicology","url":"https://pubmed.ncbi.nlm.nih.gov/26810853","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50923,"output_tokens":5534,"usd":0.117889},"stage2":{"model":"claude-opus-4-6","input_tokens":9106,"output_tokens":3143,"usd":0.186158},"total_usd":0.304047,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"TL1A (TNFSF15) is the cognate ligand for DR3 (TNFRSF25) and decoy receptor TR6/DcR3. TL1A binding to DR3 induces NF-κB activation and apoptosis in DR3-expressing cell lines, and acts as a T cell costimulator increasing IL-2 responsiveness and secretion of proinflammatory cytokines. TR6-Fc protein antagonizes these signaling events.\",\n      \"method\": \"Ligand-receptor binding assays, NF-κB reporter assays, apoptosis assays, cytokine secretion assays in vitro and in vivo T cell costimulation experiments\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (binding, reporter, functional assays) in a highly cited foundational paper; replicated by subsequent studies\",\n      \"pmids\": [\"11911831\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"TL1A-DR3 interaction triggers formation of a signaling complex containing TRADD, TRAF2, and RIP, and activates NF-κB and ERK/JNK/p38 MAPK pathways. NF-κB activation prevents DR3-mediated apoptosis via upregulation of c-IAP2; inhibition of c-IAP2 by RNAi sensitizes cells to TL1A-induced apoptosis.\",\n      \"method\": \"Co-immunoprecipitation of DR3 signaling complex, NF-κB pathway inhibitors, MAPK inhibitors, RNAi knockdown of c-IAP2, apoptosis assays in TF-1 cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reciprocal Co-IP of signaling complex, RNAi functional validation, and pathway inhibitor studies with clear mechanistic readouts\",\n      \"pmids\": [\"12882979\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"TNFRSF25 (LARD) contains a death domain and induces spontaneous apoptosis when overexpressed in 293T cells. Expression is lymphocyte-specific (T and B cells). Alternative pre-mRNA splicing generates at least 11 isoforms; full-length membrane-bound isoform predominates after T cell activation in a programmed splicing switch.\",\n      \"method\": \"Molecular cloning, overexpression in 293T cells (apoptosis assay), RT-PCR/Northern blot for isoform characterization, expression analysis across cell types\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — original cloning paper with functional overexpression assay and detailed isoform characterization; highly cited foundational study\",\n      \"pmids\": [\"9114039\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"DR3 (TNFRSF25) is the receptor responsible for TL1A-induced T cell costimulation. DR3 is required on T cells for immunopathology, local T cell accumulation, and cytokine production in EAE and allergic lung inflammation models. DR3 is not required for in vivo T cell priming or effector subset polarization. Dendritic cells are identified as the likely source of TL1A during T cell activation.\",\n      \"method\": \"DR3-deficient mouse (genetic knockout), EAE and allergic lung inflammation disease models, T cell transfer experiments, flow cytometry\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean knockout mouse with defined cellular phenotypes in multiple disease models; highly cited study\",\n      \"pmids\": [\"18571443\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"DR3 (TNFRSF25) expression is selectively elevated in Th17 cells. TL1A promotes proliferation of effector Th17 cells via DR3. TL1A-deficient dendritic cells have reduced capacity to support Th17 differentiation and proliferation. TL1A is required for optimal Th17 differentiation and effector function during EAE.\",\n      \"method\": \"TL1A-knockout mouse generation, EAE model, flow cytometry for Th17 markers, DC-T cell co-culture assays\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — TL1A KO mouse with multiple orthogonal readouts (in vitro differentiation, in vivo EAE); highly cited\",\n      \"pmids\": [\"18411337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"TNFRSF25 (TNFR25) is constitutively and highly expressed by CD4+FoxP3+ Tregs. Agonistic signaling through TNFR25 (via antibody 4C12) induces rapid and selective expansion of pre-existing Tregs in vivo (up to 30-35% of CD4+ T cells within 4 days). This Treg expansion requires TCR engagement with MHC class II, IL-2 receptor signaling, and Akt signaling, but not CD80/CD86 costimulation, and is rapamycin-insensitive. TNFR25-expanded Tregs suppress allergic lung inflammation in vivo.\",\n      \"method\": \"Agonistic monoclonal antibody (4C12) treatment in mice, flow cytometry for Treg expansion, signaling inhibitor studies, allergic lung inflammation mouse model\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (in vivo expansion, signaling pathway dissection, disease model) in a single rigorous study\",\n      \"pmids\": [\"20890040\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"TL1A and DR3 interaction promotes IFN-γ secretion in activated T cells. TL1A acts preferentially on memory CD4+/CD45RBlo T cells to induce proliferation. TL1A synergizes with IL-12/IL-18 pathway and with low-dose TCR stimulation to induce IFN-γ via an IL-18-independent pathway. DR3 mRNA undergoes alternative splicing upon lymphocyte activation, upregulating the complete/transmembrane form.\",\n      \"method\": \"RT-PCR for DR3 isoform analysis, T cell proliferation assays, cytokine secretion assays (IFN-γ), pathway inhibitor studies, two murine ileitis models\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal functional assays with defined signaling pathway dissection in two independent animal models\",\n      \"pmids\": [\"16698931\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"TWEAK does not interact with WSL-1/TRAMP (DR3) in in vitro binding assays. TWEAK binds to cells not expressing DR3 on their surface and retains biological activity in cells from DR3 knockout mice, demonstrating that DR3 is not the major receptor for TWEAK.\",\n      \"method\": \"In vitro binding assays with human and murine TWEAK, cell surface expression analysis, DR3 knockout mouse cells\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro binding assay plus KO mouse validation refuting a proposed receptor-ligand pair\",\n      \"pmids\": [\"11094155\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TNFRSF25 triggering by TL1A promotes proliferation and accumulation of antigen-specific CD8+ T cells and their differentiation into CTLs in vivo. TNFRSF25 also functions as a costimulatory receptor for memory CD8+ T cells, enhancing secondary expansion of endogenous antigen-specific memory CD8+ T cells.\",\n      \"method\": \"Ectopic TL1A expression on plasmacytomas, OT-I TCR transgenic T cell adoptive transfer, in vivo TL1A treatment, flow cytometry for CTL differentiation and proliferation\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean in vivo functional assays with transgenic T cells, single lab study\",\n      \"pmids\": [\"21688261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Atsttrin (a progranulin-derived molecule) directly binds to TNFRSF25 (DR3). The first three cysteine-rich domains (CRD) in the extracellular portion of DR3 are required for Atsttrin binding. Atsttrin inhibits the interaction between DR3 and TL1A, suppresses TL1A-stimulated target gene expression, and neutralizes TL1A-enhanced osteoclastogenesis in vitro.\",\n      \"method\": \"Direct binding assays (ELISA/pulldown), domain deletion mutants of DR3, competitive binding assay, osteoclastogenesis assay, DSS colitis model\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding with domain mapping and functional competition assays; single lab\",\n      \"pmids\": [\"24651300\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"TNFRSF25 agonist antibody (4C12)-mediated Treg expansion in vivo delays cardiac allograft rejection, associated with increased Foxp3+ Tregs within the graft and decreased infiltration of inflammatory cells.\",\n      \"method\": \"In vivo TNFRSF25 agonist antibody treatment, fully MHC-mismatched heterotopic heart transplant model, flow cytometry, histopathology, qRT-PCR\",\n      \"journal\": \"Transplantation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined cellular mechanism (Treg expansion) linked to functional outcome in transplant model; single lab\",\n      \"pmids\": [\"22902792\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TNFRSF25 ligation by TL1A leads to recruitment of TRAF2 and TRADD in primary T cells, with downstream activation of NFκB and PI3K/Akt signaling pathways. These pathways are dependent on coordinated engagement of the TCR and IL-2 receptor, leading to constitutive proliferation of CD4+FoxP3+ Tregs.\",\n      \"method\": \"Co-immunoprecipitation, signaling pathway inhibitors, primary T cell stimulation assays\",\n      \"journal\": \"Immunologic research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — review incorporating co-IP and pathway inhibitor data; mechanistic claim supported by prior experimental work\",\n      \"pmids\": [\"24242819\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The extracellular region of DR3 directly binds to Galectin-9, and Galectin-9 associates with DR3 in Tregs. DR3 agonist-mediated expansion of CD4+Foxp3+ Tregs and suppression of EAE and allergic lung inflammation requires Galectin-9, as protective effects are lost in Galectin-9-/- mice.\",\n      \"method\": \"Direct binding assay (Galectin-9 binding to extracellular DR3), in vitro stimulation of Galectin-9-/- Tregs, EAE and allergic lung inflammation models in Galectin-9-/- mice, flow cytometry\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding assay plus KO mouse in two disease models; single lab\",\n      \"pmids\": [\"28877989\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Activation of DR3 signaling by an agonistic anti-DR3 antibody increases GM-CSF production from ILC3s through the p38 MAPK pathway. GM-CSF causes accumulation of eosinophils, neutrophils and myeloid cells, leading to loss of ILC3s from the intestine in an IL-23-dependent manner and exacerbating colitis. Neutralization of TL1A by soluble DR3 ameliorates DSS and anti-CD40 antibody-induced colitis.\",\n      \"method\": \"Agonistic anti-DR3 antibody treatment, GM-CSF and IL-23 blockade/overexpression experiments, ILC3-depleted mice, DSS and anti-CD40 colitis models, flow cytometry\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal genetic and antibody-based interventions with defined signaling pathway (p38 MAPK → GM-CSF → IL-23 → ILC3 loss)\",\n      \"pmids\": [\"31358760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Direct TL1A signaling through DR3 on fibroblasts promotes intestinal fibrosis in vivo, independent of immune cell DR3 signaling. TL1A activates the Rho signal transduction pathway in fibroblasts, and inhibition of this pathway modulates TL1A-mediated fibroblast activation and migration.\",\n      \"method\": \"T cell transfer colitis model in Rag-/-, Rag-/-Dr3-/-, and fibroblast-specific DR3 knockout (Rag-/-Dr3ΔCol1a2) mice, RNA-sequencing of TL1A-stimulated fibroblasts, Rho pathway inhibition, collagen deposition assays\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-type-specific conditional KO with RNA-seq pathway identification and pharmacological validation; multiple orthogonal approaches\",\n      \"pmids\": [\"33097818\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The DR3 gene promoter CpG island is specifically hypermethylated in rheumatoid arthritis synovial cells, inhibiting DR3 gene expression and DR-3 protein levels, which may provide resistance to apoptosis in RA synovial cells.\",\n      \"method\": \"Bisulfite genomic sequencing, methylation-specific PCR, luciferase reporter assays with forced methylation by bacterial methylase Sss I, Western blotting\",\n      \"journal\": \"Arthritis and rheumatism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — promoter reporter assay with forced methylation demonstrates functional consequence; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"16508942\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"TL1A and DR3 signaling in macrophage/foam cells induces pro-atherogenic cytokines (TNF-α, MCP-1, IL-8) and matrix metalloproteinase-9 (MMP-9) when combined with IFN-γ stimulation, suggesting a role for the TL1A-DR3 pathway in atherogenesis.\",\n      \"method\": \"Anti-DR3 monoclonal antibody stimulation and recombinant TL1A treatment of THP-1 macrophage-like cells, cytokine/chemokine ELISA, MMP-9 measurement, immunohistochemistry of carotid plaques\",\n      \"journal\": \"Cytokine\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single cell line stimulation assay without receptor-specific genetic validation; no KO or reconstitution\",\n      \"pmids\": [\"15760679\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"DR3 signaling protects against acute DSS colitis; DR3-/- mice show more severe mucosal inflammation and increased mortality. DR3-/- mice are compromised in maintaining CD4+CD25+Foxp3+ regulatory T cells in response to acute mucosal damage, leading to upregulation of Th17 effector responses. TL1A-/- mice similarly show increased susceptibility and reduced Treg numbers.\",\n      \"method\": \"DR3-/- and TL1A-/- mice, DSS colitis model, Salmonella typhimurium infection model, flow cytometry for Treg and Th17 populations\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — two independent KO mouse strains with mechanistic cellular readouts in multiple disease models\",\n      \"pmids\": [\"27233964\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"DR3 activation by TL1A-Ig fusion protein or agonistic antibody (4C12) leads to Treg expansion with upregulation of activation markers ICOS, KLRG-1, PD-1, CD103, and Ki-67. DR3 agonist-mediated Treg expansion in donor mice significantly improves GVHD outcomes in MHC-mismatched hematopoietic cell transplantation recipients.\",\n      \"method\": \"TL1A-Ig fusion protein and agonistic antibody treatment, bioluminescent imaging, flow cytometry, RNA-sequencing, GVHD mouse model\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple DR3 agonist modalities with RNA-seq characterization and functional disease model; single lab\",\n      \"pmids\": [\"31379829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TL1A-DR3 axis contributes to airway remodeling in asthma. Non-secreted TL1A (nsTL1A) expressed by airway epithelial cells facilitates TGF-β-induced remodeling. Knockdown of DR3 or TL1A decreases fibrosis-associated protein expression. DR3 knockdown or TL1A knockout partly reverses airway remodeling in OVA-asthma mouse model. Downstream signaling is mediated via the NF-κB pathway.\",\n      \"method\": \"DR3 siRNA, TL1A siRNA, truncated plasmid overexpression in BEAS-2B cells, DR3 knockdown and TL1A knockout mouse asthma model, RNA-sequencing\",\n      \"journal\": \"Allergy, asthma & immunology research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — RNAi/KO in vitro and in vivo with RNA-seq pathway analysis; single lab\",\n      \"pmids\": [\"35255540\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Pre-treatment with TNFRSF25 agonistic antibody (MAbT25) before HSV infection effectively reduces severity of subsequent stromal keratitis lesions by expanding Foxp3+ Tregs. Combination of MAbT25 with galectin-9 provides superior lesion control by expanding regulatory T cells expressing CD103 while markedly reducing IFN-γ-producing effector CD4+ T cells.\",\n      \"method\": \"Agonistic TNFRSF25 antibody treatment in HSV-1 corneal infection model, flow cytometry, galectin-9 combination treatment\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional in vivo study with defined cellular mechanism; single lab\",\n      \"pmids\": [\"22811539\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TNFRSF25 (DR3) is a death-domain-containing TNF receptor superfamily member expressed primarily on lymphocytes (especially T cells and ILCs) whose sole functional ligand is TL1A (TNFSF15); TL1A binding recruits TRADD, TRAF2, and RIP into a signaling complex that activates NF-κB and PI3K/Akt pathways, promoting T cell costimulation, cytokine production, and apoptosis resistance, while constitutive DR3 signaling on FoxP3+ Tregs drives their selective expansion via TCR- and IL-2R-dependent Akt activation, and context-dependent DR3 activation on ILC3s, fibroblasts, and effector T cell subsets regulates intestinal inflammation, fibrosis, and immune homeostasis through distinct downstream pathways including p38 MAPK and Rho signaling.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"TNFRSF25 (DR3) is a death-domain-containing TNF receptor superfamily member expressed predominantly on lymphocytes that functions as a context-dependent costimulatory and pro-survival receptor linking innate and adaptive immune responses. Its sole confirmed ligand, TL1A (TNFSF15), triggers recruitment of TRADD, TRAF2, and RIP into a signaling complex that activates NF-κB, PI3K/Akt, and MAPK pathways; NF-κB-dependent upregulation of c-IAP2 prevents DR3-mediated apoptosis, converting the death-domain signal into a pro-survival and proliferative output [PMID:12882979, PMID:11911831]. DR3 is constitutively expressed at high levels on CD4+FoxP3+ regulatory T cells, where agonistic signaling drives rapid, selective Treg expansion through TCR- and IL-2R-dependent Akt activation in a Galectin-9-dependent manner, conferring protection in models of allergy, transplant rejection, GVHD, and colitis [PMID:20890040, PMID:27233964, PMID:28877989]. Beyond T cells, TL1A–DR3 signaling on ILC3s activates p38 MAPK to induce GM-CSF and modulate intestinal inflammation, and on fibroblasts activates Rho signaling to promote intestinal fibrosis, establishing DR3 as a pleiotropic regulator of mucosal immunity and tissue remodeling [PMID:31358760, PMID:33097818].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Cloning of TNFRSF25 established it as a death-domain-containing receptor with lymphocyte-restricted expression and extensive alternative splicing, raising the question of how isoform switching regulates its function after T cell activation.\",\n      \"evidence\": \"Molecular cloning, overexpression apoptosis assay in 293T cells, RT-PCR/Northern blot isoform profiling across tissues\",\n      \"pmids\": [\"9114039\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional significance of individual splice isoforms undefined\", \"Endogenous ligand unknown at this point\", \"Mechanism of splicing switch upon T cell activation not characterized\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identification of TL1A as the cognate ligand for DR3 resolved the receptor's upstream activation signal and demonstrated that TL1A–DR3 engagement activates NF-κB, induces apoptosis, and costimulates T cells for IL-2 responsiveness and cytokine secretion.\",\n      \"evidence\": \"Ligand-receptor binding assays, NF-κB reporter assays, apoptosis assays, T cell costimulation with TR6-Fc antagonist\",\n      \"pmids\": [\"11911831\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Proximal signaling complex composition not yet defined\", \"Balance between apoptosis and survival signaling unexplained\", \"Physiological relevance in vivo not tested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Biochemical dissection of the DR3 signaling complex revealed recruitment of TRADD, TRAF2, and RIP, and showed that NF-κB-mediated c-IAP2 upregulation switches DR3 from a death signal to a survival signal, resolving how a death-domain receptor promotes proliferation rather than apoptosis.\",\n      \"evidence\": \"Co-immunoprecipitation of DR3 complex, NF-κB and MAPK inhibitors, c-IAP2 RNAi in TF-1 cells\",\n      \"pmids\": [\"12882979\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Role of individual MAPKs (ERK, JNK, p38) in T cell costimulation not distinguished\", \"Signaling in primary T cells vs cell lines not compared\", \"Structural basis of complex assembly unknown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Functional studies demonstrated that TL1A–DR3 preferentially costimulates memory CD4+ T cells for IFN-γ production via synergy with IL-12/IL-18 and TCR signals, and confirmed that activation-dependent splicing upregulates the transmembrane DR3 isoform, linking isoform regulation to effector function.\",\n      \"evidence\": \"T cell proliferation/cytokine assays, RT-PCR isoform analysis, two murine ileitis models\",\n      \"pmids\": [\"16698931\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Splicing regulatory machinery not identified\", \"Relative contribution of individual cytokine synergy pathways unclear in vivo\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Genetic knockout studies in mice proved that DR3 on T cells is required for TL1A-mediated immunopathology in EAE and allergic lung disease, and identified Th17 cells as a key effector subset with elevated DR3 expression, while showing DR3 is dispensable for initial T cell priming.\",\n      \"evidence\": \"DR3-knockout and TL1A-knockout mice in EAE and allergic lung inflammation models, T cell transfer, flow cytometry\",\n      \"pmids\": [\"18571443\", \"18411337\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which DR3 selectively promotes Th17 expansion not defined at signaling level\", \"Role of DR3 on non-T cell populations not addressed\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Discovery that DR3 is constitutively expressed on FoxP3+ Tregs and that agonistic DR3 antibody drives rapid, selective Treg expansion in vivo through TCR-, IL-2R-, and Akt-dependent but rapamycin-insensitive signaling fundamentally reframed DR3 as a Treg costimulatory receptor with therapeutic potential.\",\n      \"evidence\": \"Agonistic mAb 4C12 treatment in mice, signaling pathway inhibitors, allergic lung inflammation model\",\n      \"pmids\": [\"20890040\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of rapamycin insensitivity not explained\", \"Whether Treg expansion reflects proliferation vs survival not distinguished\", \"Treg suppressive mechanism specifics undefined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"DR3 agonist-mediated Treg expansion was shown to have therapeutic efficacy in cardiac allograft rejection and HSV stromal keratitis, broadening the translational relevance and demonstrating that combination with Galectin-9 enhances regulatory outcomes.\",\n      \"evidence\": \"Agonistic anti-DR3 antibody in heart transplant and HSV-1 keratitis mouse models, flow cytometry, histopathology\",\n      \"pmids\": [\"22902792\", \"22811539\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of Galectin-9 synergy with DR3 not molecularly defined\", \"Long-term graft tolerance not established\", \"Human Treg responsiveness to DR3 agonism not tested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Loss-of-function studies in DR3−/− and TL1A−/− mice demonstrated that constitutive TL1A–DR3 signaling is required to maintain intestinal Tregs during mucosal damage, and its absence tips the balance toward pathogenic Th17 responses, establishing DR3 as a homeostatic regulator of mucosal immunity.\",\n      \"evidence\": \"DR3-KO and TL1A-KO mice in DSS colitis and Salmonella infection models, flow cytometry for Treg/Th17 balance\",\n      \"pmids\": [\"27233964\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell-intrinsic vs extrinsic requirement for DR3 on Tregs in the gut not separated\", \"Contribution of ILCs not assessed\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identification of Galectin-9 as a direct binding partner of DR3's extracellular domain, required for DR3 agonist-mediated Treg expansion and disease protection, revealed a co-receptor requirement for DR3 signaling on Tregs.\",\n      \"evidence\": \"Direct binding assay, Galectin-9-KO mice in EAE and allergic lung models, in vitro Treg stimulation\",\n      \"pmids\": [\"28877989\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether Galectin-9 modifies DR3 signaling complex composition unknown\", \"Structural basis of DR3–Galectin-9 interaction not resolved\", \"Relevance to non-Treg DR3 signaling not tested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"DR3 signaling on ILC3s was shown to activate p38 MAPK leading to GM-CSF production that drives IL-23-dependent ILC3 depletion and colitis exacerbation, revealing a cell-type-specific pro-inflammatory DR3 signaling axis distinct from its Treg-expanding role.\",\n      \"evidence\": \"Agonistic anti-DR3 antibody, GM-CSF/IL-23 blockade, ILC3-depleted mice, DSS and anti-CD40 colitis models\",\n      \"pmids\": [\"31358760\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis for differential pathway selection (p38 in ILC3 vs Akt in Tregs) not defined\", \"Role of TRADD/TRAF2 complex in ILC3 not assessed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Cell-type-specific knockout demonstrated that TL1A–DR3 signaling directly on fibroblasts, independent of immune cells, promotes intestinal fibrosis through Rho pathway activation, extending DR3 function beyond the immune system to tissue remodeling.\",\n      \"evidence\": \"Fibroblast-specific DR3 conditional KO (Rag−/−Dr3ΔCol1a2), RNA-seq of TL1A-stimulated fibroblasts, Rho inhibition\",\n      \"pmids\": [\"33097818\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific Rho GTPase family member(s) involved not identified\", \"Whether fibroblast DR3 uses TRADD/TRAF2 complex not tested\", \"Relevance to human fibrotic disease not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of DR3 signaling complex assembly, the molecular determinants that select between pro-survival (NF-κB/Akt) and pro-inflammatory (p38/Rho) outputs in different cell types, and whether DR3 agonism can be therapeutically harnessed for selective Treg expansion in humans.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal structure of DR3 ectodomain or DR3–TL1A complex\", \"Mechanism of cell-type-specific pathway selection (Akt vs p38 vs Rho) unknown\", \"Human clinical validation of DR3 agonist-driven Treg expansion absent\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 3, 5, 13, 14]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [2, 0, 5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": [0, 1, 5, 11, 13, 14]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [3, 4, 5, 6, 8, 17]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [1, 2]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"TNFSF15\",\n      \"TRADD\",\n      \"TRAF2\",\n      \"RIPK1\",\n      \"LGALS9\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}